Figure 2

Genistein inhibits HIV infection of resting CD4 T cells and macrophages. (A) Genistein inhibits HIV infection of resting CD4 T cells in additional three donors. Experimental procedures are described in Figure 1E. (B) Dosage-dependent inhibition of HIV infection of resting CD4 T cells. Resting CD4 T cells from two additional donors were pretreated with genistein at different dosages for 1 hour, and then infected with HIV-1_NL4-3 for 2 hours at 37°C in the continuous presence of these inhibitors. Following infection, cells were washed twice and a single dose of genistein was added to the culture. Cells were culture for 5 days and activated at day 5 with anti-CD3/CD28 magnetic beads (4 beads per cell). Viral replication was measured by p24 release. (C) Genistein inhibits HIV infection of primary macrophages. Human peripheral blood monocyte-derived macrophages were pretreated with genistein or DMSO (1%, control) for 1 hour, and then infected with HIV (THRO.c/2626) for 2 hours. Following infection, cells were washed to remove HIV and the inhibitor, and then continuously cultured in the absence of genistein to monitor viral replication. (D) Sunitinib inhibits HIV infection of resting CD4 T cells. Cells from two donors were pretreated with different dosages of sunitinib for 1 hour, and then infected with HIV-1_NL4-3 for 2 hours in the continuous presence of the inhibitor. Following infection, cells were washed twice and then cultured in the absence of the inhibitor for 5 days. Cells were activated at day 5 with anti-CD3/CD28 magnetic beads, and viral replication was measured by p24 release. (E) AG1478 does not inhibit HIV infection of resting CD4 T cells. Resting CD4 T cells were similarly pretreated with AG1478, and infected with HIV-1, as described in (D).